Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national blog main
san francisco blog main
6
×
biotech
boston blog main
boston top stories
national top stories
raleigh-durham blog main
san francisco top stories
new york blog main
new york top stories
raleigh-durham top stories
san diego blog main
san diego top stories
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
deals
detroit blog main
detroit top stories
indiana blog main
indiana top stories
intercept pharmaceuticals
national
seattle blog main
seattle top stories
startups
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
alnylam pharmaceuticals
celgene
clinical trials
fda
liver
medical device
nash
nonalcoholic steatohepatitis
obeticholic acid
What
disease
6
×
drug
6
×
liver
approved
bio
fatty
known
medicine
nash
new
race
roundup
therapy
adds
advanced
alliance
alnylam’s
alzheimer's
approval
areas
bad
bff
biosciences
bio’s
brain
brii
building
cancer
case
companies
conference
data
deal
deals
developer
devoted
digital
doses
earlier
easl
Language
Current search:
disease
×
drug
×
" san francisco blog main "
×
@xconomy.com
4 years ago
Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?
@xconomy.com
5 years ago
Bio Roundup: EASL Does It, Alnylam’s BFF, Gene Therapy Deals & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
6 years ago
United Therapeutics Reaches $141M Deal for PAH Drug Firm SteadyMed